Artificial Intelligence, One Day, Can Keep the Doctor Away

Artificial Intelligence, One Day, Can Keep the Doctor Away

Diagnosis by computer has long been a staple of science fiction, but fiction is rapidly becoming reality, with companies like Babylon Health and Ada Health developing artificial intelligence-based diagnostics that can be accessed by anyone with a smartphone. Some even claim that AI can outperform human physicians, which leads one to ask: will our doctors be replaced by robots?

  • by Bruce Carlson
  • October 23 2018


$11 Billion Market for Downstream Bioprocessing

Our latest market study, Downstream Bioprocessing Markets (Chromatography Columns and Resins, Membrane Adsorbers, Filtration Systems, Sensors), has found that the downstream bioprocessing market reached $11 billion in 2017


CVS-Aetna Merger and Walgreens-LabCorp Partnership: Assessing The Impact

CVS-Aetna Merger and Walgreens-LabCorp Partnership: Assessing The Impact

The two largest pharmacy chains both made very big competitive moves in the same month. CVS merged with healthcare insurance provider Aetna. Walgreens partnered with LabCorp. Both events are a good sign for the market for in vitro diagnostics, as we explain in this article.

  • by Bruce Carlson
  • October 16 2018
  • EMR


Moving the Ball Forward on EMR Connectivity for IVD Devices

Moving the Ball Forward on EMR Connectivity for IVD Devices

An interview with Serge Jonnaert, president of the IVD Industry Connectivity Consortium, by Kalorama correspondent Julie Kirkwood.


Next Generation Sequencing Continues to Make Strides: Neonatal Screening, Onco-genomics, Infectious Disease Dx, and More

Next Generation Sequencing Continues to Make Strides: Neonatal Screening, Onco-genomics, Infectious Disease Dx, and More

A quick look into some of the latest developments in the next generation sequencing segment, announced since the publication of the latest edition of our IVD report.

  • by Bruce Carlson
  • September 12 2018


Testing for Tick-Borne Diseases is a Big Business

Testing for Tick-Borne Diseases is a Big Business

Strong demand in TBD testing fueled by new threats, new innovations, increase in disease awareness, and unsatisfied patients seeking answers.

  • by Bruce Carlson
  • September 11 2018
  • IVD


5 Fast Facts About the IVD Market

The world market for diagnostics is estimated at $65 billion in 2018 and is expected to grow 4% annually to $77.8 billion by 2023. This includes all laboratory and hospital-based products, and OTC product sales. Previous editions had growth at 5-6%. growth has lowered due to reimbursement limitations. Yet there is plenty of reason for optimism too.


Theranos Finally Bleeds Out

Theranos Finally Bleeds Out

Blood-testing company Theranos, once worth $9 billion, is dissolving, having hemorrhaged billions thanks to fraudulent claims—not to mention actual fraud committed—by founder and "industry disruptor" Elizabeth Holmes.


PAMA brings huge changes to lab price testing, faces resistance from ACLA

PAMA brings huge changes to lab price testing, faces resistance from ACLA

The Protecting Access to Medicare Act (PAMA) of 2014 has surprised the industry with sweeping, potentially devastating cuts to how lab tests are reimbursed through Medicare, with a whole host of tests seeing cuts of over a third. The American Clinical Laboratory Association (ACLA) is fighting back with a lawsuit over the methodology of the Centers for Medicare and Medicaid’s (CMS) data collection in determining the new pricing scheme. The American Association for Clinical Chemistry (AACC) also weighs in, and asserts that labs will need to make some big changes if they want to survive.

  • by Bruce Carlson
  • August 28 2018


$77.8 Billion-Dollar IVD Market by 2023: New Report

$77.8 Billion-Dollar IVD Market by 2023: New Report

Drivers outweigh limiters when it comes to the IVD market, according to Kalorama Information's latest IVD report, the 11th edition. Test procedures are up and will be up, but cost-cutting form major payors is limiting marketing growth slightly faster than emergings can make up for it. This article highlights some of the key findings of the report.